EP1644319A1 - Novel halo-substituted active methylene compounds - Google Patents

Novel halo-substituted active methylene compounds

Info

Publication number
EP1644319A1
EP1644319A1 EP03817135A EP03817135A EP1644319A1 EP 1644319 A1 EP1644319 A1 EP 1644319A1 EP 03817135 A EP03817135 A EP 03817135A EP 03817135 A EP03817135 A EP 03817135A EP 1644319 A1 EP1644319 A1 EP 1644319A1
Authority
EP
European Patent Office
Prior art keywords
formula
compounds
formula iii
compound
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03817135A
Other languages
German (de)
French (fr)
Other versions
EP1644319A4 (en
Inventor
Joy c/o Biocon Limited MATHEW
Tom Thomas c/o Biocon Limited PUTHIAPARAMPIL
Madhavan c/o Biocon Limited SRIDHARAN
Shanker Padudevastana c/o Biocon Limited SATHYA
Sambasivam c/o Biocon Limited GANESH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of EP1644319A1 publication Critical patent/EP1644319A1/en
Publication of EP1644319A4 publication Critical patent/EP1644319A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Definitions

  • the compounds of formula I can be prepared by a novel process comprising, a) a) halogenation of compound of formula II to afford a compounds of formula HI, b) reaction of compounds of formula III with compounds of formula IV.
  • G any alkyl or aryl
  • HMG Co-A reductase inhibitors are important intermediates for the preparation of drug molecules especially, HMG Co-A reductase inhibitors.
  • the HMG Co-A reductase inhibitors are useful as inhibitors of the enzyme 3-hydroxy-3- methylglutaryl-coenzyme A reductase (HMG CoA reductase) and are thus useful as hvpolipidemic or hypocholesterolemic agents.
  • G any alkyl or aryl
  • FORMULA I The process of the present invention is new, economical, and commercially feasible method for preparing intermediates used for the preparation of HMG CoA reductase inhibitors.
  • reaction between compounds of formula II and III is carried out in the presence of reagents selected from Bromine, N-bromosuccinimide, thionyl chloride, Br 2 (CN) 2 , 4-(dimethylamino)pyridinium bromide or any such suitable halogenating agent.
  • reagents selected from Bromine, N-bromosuccinimide, thionyl chloride, Br 2 (CN) 2 , 4-(dimethylamino)pyridinium bromide or any such suitable halogenating agent.
  • the compounds of formula III can be further used for preparation of 4-
  • Fluoro- ⁇ -[2-methyl-l-oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzene butane amide which is key intermediate for manufacture of [R-(R*,R*)]-2-(4-Fluorophenyl)-B,D-Dihydroxy- 5-(l-Methylethyl)-3-Phenyl-4-[(Phenyl amino) Carbonyl]-lh-Pyrrole-l-Heptanoic Acid, by reacting with compound of formula IV.
  • the reaction between compounds of formula III and formula IV is carried out in the presence of reagents selected from Lithium diisopropylamide, sodium hydride n-butyllithium, sodium ethoxide or any such suitable base.
  • Halogenation X any halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A novel process for the preparation of compounds of formula (I) by employing novel halo-substituted active methylene compounds of formula (III) and process of preparation thereof.

Description

X = any halogen
Formula III The present invention also relates to novel process for preparation compounds of formula I.
G = any alkyl or aryl Formula I
As mentioned earlier the compounds of formula I can be prepared by a novel process comprising, a) a) halogenation of compound of formula II to afford a compounds of formula HI, b) reaction of compounds of formula III with compounds of formula IV.
Formula II
X = any halogen
Formula III
G = any alkyl or aryl
Formula IV
Detailed Description of the invention
Compounds of formula I are important intermediates for the preparation of drug molecules especially, HMG Co-A reductase inhibitors. The HMG Co-A reductase inhibitors are useful as inhibitors of the enzyme 3-hydroxy-3- methylglutaryl-coenzyme A reductase (HMG CoA reductase) and are thus useful as hvpolipidemic or hypocholesterolemic agents.
G = any alkyl or aryl
FORMULA I The process of the present invention is new, economical, and commercially feasible method for preparing intermediates used for the preparation of HMG CoA reductase inhibitors.
The reaction between compounds of formula II and III is carried out in the presence of reagents selected from Bromine, N-bromosuccinimide, thionyl chloride, Br2(CN)2, 4-(dimethylamino)pyridinium bromide or any such suitable halogenating agent. The compounds of formula III can be further used for preparation of 4-
Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide which is key intermediate for manufacture of [R-(R*,R*)]-2-(4-Fluorophenyl)-B,D-Dihydroxy- 5-(l-Methylethyl)-3-Phenyl-4-[(Phenyl amino) Carbonyl]-lh-Pyrrole-l-Heptanoic Acid, by reacting with compound of formula IV. The reaction between compounds of formula III and formula IV is carried out in the presence of reagents selected from Lithium diisopropylamide, sodium hydride n-butyllithium, sodium ethoxide or any such suitable base.
The following non-limiting examples illustrate the inventors' preferred method for preparing the compounds of the invention.
EXAMPLES
Example 1
Preparation of 2-Bromo-4-methyl-3-oxo-pentanoic acid phenylamide:
To a solution of 4-Methyl-3-oxo-pentanoic acid phenylamide (10 g, 0.048 mol) in chloroform (100 mL), liquid bromine (7.8 g, 0.048 mol) was added. After stirring for 30 minutes, the reaction mixture was concentrated and product was isolated by column chromatography(silica gel: 60-120 mesh, eluent: Pet. Ether/ethyl acetate-
60:40)
Yield: 11.0 g, 80%
Example 2 Preparation of 2-Bromo-4-methyl-3-oxo-pentanoic acid phenylamide:
To a solution of 4-Methyl-3-oxo-pentanoic acid phenylamide (10 g, 0.048 mol) in acetone 100 mL), N-bromosuccinimide (8.5 g, 0.048 mol) was added. After stirring for 3 hours, the reaction mixture was concentrated and product was isolated by crystallization from Pet. Ether/ethyl acetate. Yield: 12.5 g, 92% Example 3
Preparation of 4-Fluoro-α- [2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide:
To a chilled solution of dϋsopropylamine (8 mL, 0.056 mol) in dry THF(50 mL), n-butyl lithium (35 mL, 1.6 M, 0.056 mol) in hexane was added dropwise under nitrogen atmosphere, maintaining the temperature between -10° C and -25° C and stirred for 30 minutes at the same temperature. A solution of l-(4-Fluoro-phenyl)-2- phenyl-ethanone (10 g, 0.047 mol) in THF (20 mL) was added to the reaction mixture dropwise, maintaining the temperature between -60° C and -78° C and stirred for 1 hour at the same temperature. 2-Bromo-4-methyl-3-oxo-pentanoic acid, phenylamide (13.4 g, 0.047 mol) in THF (30 mL) was added dropwise to the reaction mixture , maintaining the temperature between -60° C and -78° C and stirred for 30 minutes. The reaction mixture was slowly warmed 10-15° C, over a period of 1 hour and quenched with water (50 mL). The product was extracted with ethyl acetate (2 x 50 mL). Combined organic extract was washed with water (2 x 50 mL) brine (2 x 50 mL) and concentrated to obtain title compound. Yield: 16 g, 85%. Example 4
Preparation of 4-Fluoro-α- [2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide:
To a chilled solution of diisopropylamine (8 mL, 0.056 mol) in dry THF (50 mL), n-butyl lithium (35 mL, 1.6 M, 0.056 mol) in hexane was added dropwise under nitrogen atmosphere, maintaining the temperature between —10° C and —25° C and stirred for 30 minutes at the same temperature. A solution of l-(4-Fluoro- ρhenyl)-3-methyl-butan-l-one (8.4 g, 0.047 mol) in THF (20 mL) was added to the reaction mixture dropwise, maintaining the temperature between —60° C and —78° C and stirred for 1 hour at the same temperature. 2-Bromo-4-methyl-3-oxo-pentanoic acid phenylamide (13.4 g, 0.047 mol) in THF (30 mL) was added dropwise to the reaction mixture , maintaining the temperature between —60° C and -78° C and stirred for 30 minutes. The reaction mixture was slowly warmed 10-15° C, over a period of 1 hour and quenched with water (50 mL). The product was extracted with ethyl acetate (2 x 50 mL). Combined organic extract was washed with water (2 x 50 mL) brine (2 x 50 mL) and concentrated to obtain title compound. Yield: 15 g, 87%.
Scheme I:
Halogenation X = any halogen

Claims

CLAIMSWe claim:
1. A process for preparing compound of formula I
G = any alkyl or aryl
Formula I comprising the steps of reaction of the compound of formula III with compounds of formula IV to obtain compound of formula I
X = any halogen
Formula III
G = any alkyl or aryl Formula IV
2. A process as in claim 1, wherein the reaction between compounds of formula III and formula IV is carried out in the presence of reagents selected from lithium dϋsopropylamide, sodium hydride n-butyllithium, sodium ethoxide or any such suitable base.
3. A process as in claim 1, wherein the compounds of formula III is prepared
X = any halogen FORMULA III by halogenation of compound of formula II to afford a compound of formula II.
Formula II
4. A process as in claim 3, wherein the halogenation is carried out in the presence of reagents selected from Bromine, N-bromosuccinimide, thionyl chloride, Br2(CN)2, 4-(dimethylamino)pyridinium bromide or any such suitable halogenating agent.
5. An intermediate of formula III
X = any halogen Formula III
EP03817135A 2003-06-09 2003-06-09 Novel halo-substituted active methylene compounds Withdrawn EP1644319A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2003/000216 WO2004108660A1 (en) 2003-06-09 2003-06-09 Novel halo-substituted active methylene compounds

Publications (2)

Publication Number Publication Date
EP1644319A1 true EP1644319A1 (en) 2006-04-12
EP1644319A4 EP1644319A4 (en) 2007-10-31

Family

ID=33495848

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03817135A Withdrawn EP1644319A4 (en) 2003-06-09 2003-06-09 Novel halo-substituted active methylene compounds

Country Status (4)

Country Link
EP (1) EP1644319A4 (en)
JP (1) JP2006527164A (en)
AU (1) AU2003242989A1 (en)
WO (1) WO2004108660A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510797A (en) * 2004-08-26 2008-04-10 バイオコン・リミテッド Process for producing 4-fluoro-α- [2-methyl-1-oxopropyl] γ-oxo-N-β-diphenylbenzenebutanamide
CN114195670B (en) * 2021-12-31 2024-03-15 河南豫辰药业股份有限公司 Refining method of atorvastatin mother nucleus M4

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6254257A (en) * 1985-05-11 1987-03-09 Konishiroku Photo Ind Co Ltd Silver halide photographic sensitive material
WO2001072706A1 (en) * 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO2002057274A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited A process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds
WO2003004457A2 (en) * 2001-07-04 2003-01-16 Ciba Specialty Chemicals Holding Inc. Preparation process for atorvastatin and intermediates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6254257A (en) * 1985-05-11 1987-03-09 Konishiroku Photo Ind Co Ltd Silver halide photographic sensitive material
WO2001072706A1 (en) * 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO2002057274A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited A process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds
WO2003004457A2 (en) * 2001-07-04 2003-01-16 Ciba Specialty Chemicals Holding Inc. Preparation process for atorvastatin and intermediates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004108660A1 *

Also Published As

Publication number Publication date
JP2006527164A (en) 2006-11-30
WO2004108660A1 (en) 2004-12-16
EP1644319A4 (en) 2007-10-31
AU2003242989A1 (en) 2005-01-04

Similar Documents

Publication Publication Date Title
CA1334417C (en) Process for preparing pyridine-2,3-dicarboxylic acid compounds
CZ282922B6 (en) Synthesis process of (4r-cis)-1,1-dimethylethyl-6-cyanomethyl -2,2-dimethyl-1,3-dioxan-4-acetate and intermediates used in such process
US4931565A (en) Process for production of 2-pyrazolin-5-ones
Jiang et al. Lewis acid promoted alkynylation of imines with terminal alkynes: simple, mild and efficient preparation of propargylic amines
Firooznia et al. Enantioselective synthesis of 4-substituted phenylalanines by cross-coupling reactions
US5359090A (en) Alkoxymethylation of pyrroles
WO2006097909A1 (en) Preparation of an atorvastatin intermediate using a paal-knorr condensation
EP1644319A1 (en) Novel halo-substituted active methylene compounds
WO2003004457A2 (en) Preparation process for atorvastatin and intermediates
WO2007096751A1 (en) Process for the preparation of atorvastatin calcium
US20050113607A1 (en) Novel halo-substituted active methylene compounds
US20050176987A1 (en) Method for producing vinyl, aryl and heteroaryl acetic acids and derivatives thereof
CN100368386C (en) Process for synthesizing (+/-)p-fluoro-2(2-methyl-propionyl)-4-oxy-N,3-diphenyl-phenylbutylamide
JP5149803B2 (en) Method for producing succinimide compound
US5068390A (en) 1,1,1-trifluoro-2-propene compounds
KR20040039430A (en) Process for producing (2-nitrophenyl)acetonitrile derivative and intermediate therefor
KR100475244B1 (en) Preparation of an intermediate for the synthesis of atorvastatin
US5977414A (en) 2,3-Dihalogeno-6-trifluoromethylbenzene derivatives and processes for the preparation thereof
US5750726A (en) Process for the manufacture of 2-aryl-5-perfluoroalkylpyrrole derivatives and intermediates useful therefor
US5777132A (en) Process for the manufacture of 2-aryl-5 perfluoroalkylpyrrole derivatives
CA2138587A1 (en) Process for the preparation of 2,4,5-tribromopyrrole-3-carbonitrile
JP2009516728A (en) Methods and compounds
WO2004103957A1 (en) Novel dithioketal
JP4163771B2 (en) 2-Aryl-5-perfluoroalkylpyrrole derivatives and methods for producing useful intermediates thereof
US5981803A (en) Process for the preparation of chloro-benzoyl chlorides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20071002

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 235/80 20060101AFI20070926BHEP

17Q First examination report despatched

Effective date: 20071126

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090324